Summary & Overview

Bone Diseases and Arthropathies with MCC: Inpatient Reimbursement Overview

DRG 553 encompasses inpatient stays for bone diseases and arthropathies with a Major Complication or Comorbidity, indicating increased clinical severity and resource use. Correct classification affects Medicare inpatient reimbursement because the Major Complication or Comorbidity status elevates the Diagnosis-Related Group weight and associated prospective payment.

Bone Diseases and Arthropathies with MCCDRG Bone Diseases and Arthropathies with MCCDRG 553Diagnosis-Related GroupInpatient ReimbursementMedicareOrthopedicsRheumatologyMusculoskeletal SurgeryHospital Coding

DRG 553 Overview

DRG 553 covers hospital inpatient cases involving bone diseases and arthropathies when a Major Complication or Comorbidity is present, reflecting higher clinical severity and resource needs. This Diagnosis-Related Group is used to classify admissions such as severe infections, fractures with significant comorbidity, and advanced inflammatory or degenerative joint conditions complicated by acute medical issues. It matters for Medicare payment because the presence of a Major Complication or Comorbidity raises the relative weight and prospective payment, aligning reimbursement with increased expected costs of care. Accurate coding of principal and secondary diagnoses influences assignment to this Diagnosis-Related Group and subsequent Medicare inpatient reimbursement.

Clinical Trials

Acute surgical and perioperative management trials focusing on complex fractures, osteomyelitis requiring debridement, or rapidly progressive arthropathies with systemic complications. These studies enroll hospitalized patients classified under DRG 553 who require urgent operative intervention and intensive perioperative care, comparing protocols for timing of surgery, antibiotic strategies, and blood management to reduce length of stay and perioperative complications. Results are highly relevant to providers for optimizing in-hospital pathways and to payers because improvements can lower complication-related costs and readmission rates.
Comparative effectiveness studies of inpatient multimodal pain control and mobility protocols for severe bone disease or arthropathy exacerbations with major comorbidities. These trials recruit older adults or medically complex patients admitted for painful bone or joint conditions with major complications, evaluating outcomes such as in-hospital opioid use, functional recovery at discharge, and early post-discharge resource utilization across different analgesic regimens and physical therapy intensities. Payers and hospital administrators rely on this evidence to balance clinical effectiveness, length of stay, and downstream costs associated with prolonged rehabilitation or discharge to higher-acuity post-acute care.
Post-discharge outcomes and care-transition research assessing readmission prevention, infection surveillance, and long-term functional trajectories after hospitalization for bone diseases and arthropathies with major complications. These prospective cohort or pragmatic trials follow patients after discharge to measure rates of reinfection, prosthetic failure, mobility, and healthcare utilization, testing care-coordination interventions such as structured outpatient follow-up, home health models, or remote monitoring. Findings inform discharge planning, bundled-payment models, and payer strategies to reduce costly readmissions and improve long-term outcomes for this high-risk DRG population.

Related Codes

472-CERVICAL-SPINAL-FUSION-WITH-CC

Cervical Spinal Fusion with CC: Inpatient Reimbursement Overview

545-CONNECTIVE-TISSUE-DISORDERS-WITH-MCC

Connective Tissue Disorders with MCC: Inpatient Reimbursement Overview

556-SIGNS-AND-SYMPTOMS-OF-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITHOUT-MCC

Signs and Symptoms of Musculoskeletal System and Connective Tissue without MCC: Inpatient Reimbursement Overview

487-KNEE-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-OF-INFECTION-WITHOUT-CC-MCC

Knee Procedures with Principal Diagnosis of Infection without CC/MCC: Inpatient Reimbursement Overview

477-BIOPSIES-OF-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITH-MCC

Biopsies of Musculoskeletal System and Connective Tissue with MCC: Inpatient Reimbursement Overview

451-SINGLE-LEVEL-SPINAL-FUSION-EXCEPT-CERVICAL-WITHOUT-MCC

Single Level Spinal Fusion Except Cervical without MCC: Inpatient Reimbursement Overview

486-KNEE-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-OF-INFECTION-WITH-CC

Knee Procedures with Principal Diagnosis of Infection with CC: Inpatient Reimbursement Overview

566-OTHER-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-DIAGNOSES-WITHOUT-CC-MCC

Other Musculoskeletal System and Connective Tissue Diagnoses without CC/MCC: Inpatient Reimbursement Overview

558-TENDONITIS-MYOSITIS-AND-BURSITIS-WITHOUT-MCC

Tendonitis, Myositis and Bursitis without MCC: Inpatient Reimbursement Overview

549-SEPTIC-ARTHRITIS-WITH-CC

Septic Arthritis with Complication or Comorbidity: Inpatient Reimbursement Overview

Showing 1–10 of 104

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.